News

CPhI 2021 in Milan

As an exhibitor at this year's CPhI trade show in Milan, we were pleased to have personal contact with numerous visitors and interested parties. Intensive discussions with business partners as well as high-quality consultations on [...]

  • FDA approved

FDA Approval for Lichtenheldt

Lichtenheldt produces a drug with a novel therapeutic principle for a rare but very serious disease. In preparation for FDA approval under the accelerated procedure as an "orphan drug", Lichtenheldt was approved by the FDA.

  • Compounding Center Werkbank

New Compounding Center

After 8 months of construction, the Compounding Center was put into operation in June 2021. This enlarged the production area for bulk production by 440 m² and meets the most modern requirements. With the help [...]

Lichtenheldt Virtual Event

In a normal year, the pharmaceutical world would actually have traveled to Milan to participate in the CPhI. But what is normal in 2020? That's why we at Lichtenheldt have come up with something special [...]

Contact Person:

Contact
04554 90 70 0
info@lichtenheldt.de